Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
Instagram is introducing a new tool that lets you see and control your algorithm, starting with Reels, the company announced on Wednesday. The new tool, called “Your Algorithm,” lets you view the ...
Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...
Social media companies and their respective algorithms have repeatedly been accused of fueling political polarization by promoting divisive content on their platforms. Now, two U.S. Senators have ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...
Is your feature request related to a problem or challenge? Currently, AlgoVisualizer does not include any visualization for constraint-based problems like Sudoku. This makes it difficult for learners ...
Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...
Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...
An artificial-intelligence algorithm that discovers its own way to learn achieves state-of-the-art performance, including on some tasks it had never encountered before. Joel Lehman is at Lila Sciences ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback